^
    Back
    Association details:
    Biomarker:GNA13 mutation
    Cancer:Follicular Lymphoma
    Regimen: (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2020
    Title:

    MUTATIONAL PROFILE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA AND CORRELATION WITH OUTCOME AFTER TREATMENT WITH INMUNOCHEMOTHERAPY

    Published date:
    06/12/2020
    Excerpt:
    This is a retrospective study from 2 centers that included all consecutive patients with FL grade 1-3a treated in first line with R-CHOP/CHOP-like or R-bendamustine. we found that the presence of mutations in GNA13 and GNAI2, that encode G-proteins mostly involved in dissemination of germinal-center B-cells and migration, was associated with better PFS...